secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stereotaxis, Inc. (STXS)
CIK:        0001289340
Form:       8-K
Filed at:   2026-08-11T20:05:17+00:00
Accession:  0001493152-26-037113
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stereotaxis Q2 2026 revenue $7.7M; robotic catheter revenue tops $1M, up 270% sequentially
--------------------------------------------------------------------------------

- Q2 2026 revenue $7.7M; system revenue $1.5M (vs $3.0M year-ago), recurring revenue $6.2M (vs $5.8M year-ago).
- Net loss widened to $4.5M from $3.8M year-ago; adjusted net loss $2.0M vs $1.3M; operating loss $4.6M.
- Robotic catheter revenue surpassed $1M in the quarter, growing 270% sequentially; first US GenesisX purchase announced.
- Cash $10.5M with no debt at June 30, 2026; expects recurring revenue ~$7M in Q3 and ~$8M in Q4 2026.
- Completed Robocath acquisition; multiple Synchrony OR systems sold after April FDA clearance; cash flow profitability targeted 1H 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1289340/000149315226037113/0001493152-26-037113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1289340/000149315226037113/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer